CD274, Also known as PDL1, it is a ligand that binds to the common receptor PD1 on T cells and is used to block T cell activation. PD1 expression has been observed in various cancers, including melanoma and non-small cell lung cancer. The interaction between PD1 and PDL1 is considered a possible mechanism by which tumors evade immune responses. Many checkpoint blockade inhibitors have been developed, including pembrolizumab and nivolumab, which target the PD1/PDL1 interaction, allowing T cells to recognize tumor cells without being inactivated by the tumor.
Alpha Lifetech offers flexible ordering options for biosimilar antibody products, providing both small and large quantities to suit different needs.